Is Surgery-first Still a Reasonable Option in the Era of Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer?
暂无分享,去创建一个
M. Abdelrahim | R. Ghobrial | F. Baio | A. Saharia | C. Mobley | K. Heyne | Ahmed Elaileh | Lucy M Potter
[1] J. Trojan,et al. Randomized multicenter phase II/III study with adjuvant gemcitabine versus neoadjuvant/adjuvant FOLFIRINOX in resectable pancreatic cancer: The NEPAFOX trial. , 2015, Journal of Clinical Oncology.
[2] Y. Takeda,et al. A Prospective, Open-Label, Multicenter Phase 2 Trial of Neoadjuvant Therapy Using Full-Dose Gemcitabine and S-1 Concurrent with Radiation for Resectable Pancreatic Ductal Adenocarcinoma , 2019, Annals of Surgical Oncology.
[3] J. Berlin,et al. APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma. , 2019, Journal of Clinical Oncology.
[4] T. Conroy,et al. Adjuvant treatment of pancreatic cancer. , 2019, Current opinion in oncology.
[5] T. Seufferlein,et al. Treatment of pancreatic cancer-neoadjuvant treatment in resectable pancreatic cancer (PDAC). , 2019, Translational gastroenterology and hepatology.
[6] R. Pęksa,et al. Primarily resectable pancreatic adenocarcinoma - to operate or to refer the patient to an oncologist? , 2019, Critical reviews in oncology/hematology.
[7] A. Bradley,et al. Neoadjuvant therapy versus upfront surgery for potentially resectable pancreatic cancer: A Markov decision analysis , 2019, PloS one.
[8] S. Bates,et al. Neoadjuvant Treatment for Pancreatic Cancer. , 2019, Seminars in oncology.
[9] Jeffrey E. Lee,et al. Chemotherapy Versus Chemoradiation as Preoperative Therapy for Resectable Pancreatic Ductal Adenocarcinoma: A Propensity Score Adjusted Analysis , 2019, Pancreas.
[10] G. Honda,et al. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). , 2019, Japanese journal of clinical oncology.
[11] P. Philip,et al. SWOG S1505: Initial findings on eligibility and neoadjuvant chemotherapy experience with mFOLFIRINOX versus gemcitabine/nab-paclitaxel for resectable pancreatic adenocarcinoma. , 2019, Journal of Clinical Oncology.
[12] P. Philip,et al. Adjuvant treatment of surgically resectable pancreatic ductal adenocarcinoma. , 2019, Clinical advances in hematology & oncology : H&O.
[13] Thierry Lecomte,et al. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer , 2018, The New England journal of medicine.
[14] W. Uhl,et al. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group , 2018, BMC Cancer.
[15] A. Zwinderman,et al. Preoperative Chemoradiotherapy Potentially Improves Outcome for (Borderline) Resectable Pancreatic Cancer: Preliminary Results of the Dutch Randomized Phase III PREOPANC Trial , 2018, International Journal of Radiation Oncology*Biology*Physics.
[16] K. Badiozamani,et al. Gemcitabine and Taxane Adjuvant Therapy with Chemoradiation in Resected Pancreatic Cancer: A Novel Strategy for Improved Survival? , 2018, Annals of Surgical Oncology.
[17] C. Haglund,et al. Neoadjuvant therapy offers longer survival than upfront surgery for poorly differentiated and higher stage pancreatic cancer , 2017, Acta oncologica.
[18] T. George,et al. The Multidisciplinary Approach to Localized Pancreatic Adenocarcinoma , 2017, Current Treatment Options in Oncology.
[19] K. Lassen,et al. Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) – study protocol for a national multicentre randomized controlled trial , 2017, BMC Surgery.
[20] B. Dörken,et al. CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] T. Buanes. Role of surgery in pancreatic cancer , 2017, World journal of gastroenterology.
[22] M. Büchler,et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial , 2017, The Lancet.
[23] N. Sata,et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01) , 2016, The Lancet.
[24] P. Bachellier,et al. Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy , 2015, Oncology.
[25] A. Hinke,et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. , 2013, JAMA.
[26] I. Francis,et al. Pancreatic ductal adenocarcinoma staging , 2013, Cancer imaging : the official publication of the International Cancer Imaging Society.
[27] M. Lesurtel,et al. Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study) , 2011, BMC Cancer.
[28] Jeffrey E. Lee,et al. Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative Therapy , 2006, Annals of Surgical Oncology.